Apabetalone: A Potential Alzheimer's Play?

New Zacks report doesn't budge on its previous CAD $5.00 valuation. Projects top-line BETonMACE readout H1 2019 and that cash on hand from Third Eye loan enough to get to top-line data. Nice focus on Alzehimers. Touches on plans for US listing. BETonMACE trial design diagram incorrectly shows dosing for 104 weeks; Resverlogix has amended trial protocol to allow for dosing beyond 104 weeks...potentially until end of trial.

"The BETonMACE trial is event dependent and will conclude upon achieving 250 MACE events. We had expected the 75% sample size re-estimation analysis at 188 patient events to be announced in the spring or summer, however, it appears that this has not yet taken place. We see a few possible scenarios that could contribute to this slower than expected rate of MACE events.

• The population that has enrolled in the study has a much lower than expected event rate overall,
• Apabetalone is effective in reducing the MACE rate,
• A combination of these two factors or other unknown factor.

While the slow pace is delaying the completion of the trial, we do not believe it detracts from a positive outcome. Our best guess is that we will see the full 250 events complete in the first few months of 2019."